References
- Kahn SE. Clinical review 135: the importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 2001;86:4047–58
- Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005;28:995–1000
- Palmer AJ, Roze S, Valentine WJ, et al. What impact would pancreatic beta-cell preservation have on life expectancy, quality-adjusted life expectancy and costs of complications in patients with type 2 diabetes? A projection using the CORE diabetes model. Curr Med Res Opin 2004;20: S59–S66
- Charbonnel B, Schernthaner G, Brunetti P, et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005;48:1093–104
- Hanefeld M, Brunetti P, Schernthaner GH, et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with Type 2 diabetes. Diabetes Care 2004;27:141–7
- Tan M, Baksi A, Kubalski P, et al.; for the GLAL Study Group. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005;28: 544–50
- Diani AR, Sawada G, Wyse B, et al. Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004;286:E116–E122
- Ishida H, Takizawa M, Ozawa S, et al. Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress. Metabolism 2004;53:488–94
- Miyazaki Y, Matsuda M, DeFronzo RA. Dose–response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25: 517–23
- Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabetic Med 2004;21:568–76
- Perriello G, Pampanelli S, Di Pietro C, Brunetti P. Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes. Diabetic Med 2006;23: 246–52
- Urquhart R, Edwards G, Maher LJ, et al. The coefficient of failure for HbA1C in drug naïve patients treated with pioglitazone, metformin or gliclazide monotherapy [Abstract]. Diabetes 2003;52:A137
- Dormandy JA, Charbonnel B, Eckland EJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes: a randomized trial of pioglitazone. The PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events). Lancet 2005;366:1279–89